These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1196 related items for PubMed ID: 15610050

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 3. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

  • 4. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 5. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH, Bachenheimer BS.
    Drugs; 2000 Jul 08; 60(1):55-93. PubMed ID: 10929930
    [Abstract] [Full Text] [Related]

  • 6. Diabetic dyslipidemia.
    Kreisberg RA.
    Am J Cardiol; 1998 Dec 17; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [Abstract] [Full Text] [Related]

  • 7. Beneficial effects of statins on endothelial dysfunction and vascular stiffness.
    Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C.
    Curr Vasc Pharmacol; 2007 Jul 17; 5(3):227-37. PubMed ID: 17627566
    [Abstract] [Full Text] [Related]

  • 8. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov 17; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 9. Endothelial Dysfunction in Obesity and Therapeutic Targets.
    Engin A.
    Adv Exp Med Biol; 2024 Nov 17; 1460():489-538. PubMed ID: 39287863
    [Abstract] [Full Text] [Related]

  • 10. Diabetic dyslipidaemia: insights for optimizing patient management.
    Vergès B.
    Curr Med Res Opin; 2005 Nov 17; 21 Suppl 1():S29-40. PubMed ID: 15811197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T, Abbasi F, Lamendola C, Leary E, Reaven GM.
    Metabolism; 2002 Oct 17; 51(10):1355-9. PubMed ID: 12370858
    [Abstract] [Full Text] [Related]

  • 18. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs.
    Toth PP.
    Drugs; 2010 Jul 30; 70(11):1363-79. PubMed ID: 20614945
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.